Prazoto IV contains pantoprazole. It is a drug belonging to a class known as proton pump inhibitors. It helps in reduction of acid in stomach. It produces immediate relief in heart burns. It is potent inhibitor in gastric acid reduction.
- Short term treatment for erosive esophagitis associated with GERD
- It is indicated for the maintenance of healing of erosive esophagitis
- Reduction in the symptoms of heartburn in day and night time
- In hypersecretory symptoms
- Zollinger-Ellison syndrome
- Short term treatment in patients of five year and above
Once daily by intravenous infusion for 7 to 10 days.
It produces its action by formation of covalent bond to two sides of the (H+,K+)- ATPase enzyme system on the secretory surface of the gastric parietal cells is the final step in gastric acid production which is inhibited by pantoprazole.
It is well absorbed in body. It undergoes first pass metabolism with bioavailability of 77% .
The drug protein binding is 98%. The metabolism of the drug through cytochrome P450 (CYP) in liver. The CYP2C19 causes demethylation and subsequent sulfation. The metabolism of the drug also includes oxidation by CYP3A4.
Elimination of the drug through urine is about 71% and 18% through feces by biliary excretion.
- Patient with hypersensitivity reaction
- Anaphylactic shock
- Acute intestinal nephritis
- Long term use causes acute interstitial nephritis
- Long treatment with acid suppressing drug causes malabsorption
- Patient with high risk of Clostridium difficileassociated diarrhea treating with acid suppressing drug
- Can increase the risk of osteoporosis
- Should not be prescribed for long term treatment because it can even cause gastrointestinal tumors.